PT  - JOURNAL ARTICLE
AU  - Shuhui Lim
AU  - Regina Khoo
AU  - Yu-Chi Juang
AU  - Pooja Gopal
AU  - Huibin Zhang
AU  - Constance Yeo
AU  - Khong Ming Peh
AU  - Jinkai Teo
AU  - Simon Ng
AU  - Brian Henry
AU  - Anthony W. Partridge
TI  - bioPROTACs establish RAS as a degradable target and provide novel RAS biology insights
AID  - 10.1101/2020.06.26.174565
DP  - 2020 Jan 01
TA  - bioRxiv
PG  - 2020.06.26.174565
4099  - http://biorxiv.org/content/early/2020/06/27/2020.06.26.174565.short
4100  - http://biorxiv.org/content/early/2020/06/27/2020.06.26.174565.full
AB  - Mutations to RAS proteins (H-, N-, and K-RAS) are amongst the most common oncogenic drivers and tumors harboring these lesions are some of the most difficult to treat. Although the recently discovered covalent small molecules against the KRASG12C mutant have shown promising efficacy against lung cancers, traditional barriers remain for drugging the more prevalent KRASG12D and KRASG12V mutants. Targeted degradation has emerged as an attractive alternative approach but for KRAS, identification of the required high-affinity ligands continues to be a challenge. Another significant hurdle is the discovery of a hybrid molecule that appends an E3 ligase-recruiting moiety in a manner that satisfies the precise geometries required for productive polyubiquitin transfer while maintaining favorable drug-like properties. As a tool to gain insights into the advantages and feasibility of KRAS targeted-degradation, we applied the bioPROTAC approach. This workflow centers on the intracellular expression of a chimeric protein consisting of a high-affinity target-binding domain fused to an engineered E3 ligase adapter. We generated a series of anti-RAS bioPROTACs that span different RAS isoform/nucleotide-state specificities and leverage different E3 ligases. Overall, our results provide definitive evidence for the degradability of RAS proteins. We further elucidate the functional consequences of RAS degradation, the susceptibility and degradation kinetics of various mutant KRAS, and the prevalence of different nucleotide-states in WT and mutant KRAS. Finally, if delivery challenges can be addressed, anti-RAS bioPROTACs will be exciting candidates for clinical development.Competing Interest StatementThe authors have declared no competing interest.